LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Aktien・Cellectar Biosciences Inc

C
Cellectar Biosciences Inc

Geschlossen

2.74 -7.12

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.7

Max

2.95

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+247.81% upside

Cellectar Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juni 2026, 20:30 UTC

Ergebnisse

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2. Juni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. Juni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Juni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. Juni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. Juni 2026, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. Juni 2026, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. Juni 2026, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. Juni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. Juni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. Juni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Juni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. Juni 2026, 21:00 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. Juni 2026, 20:46 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:38 UTC

Ergebnisse

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. Juni 2026, 20:21 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:12 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Product Rev $594M

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Adj EPS 85c >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Loss $177M >PANW

Peer-Vergleich

Kursveränderung

Cellectar Biosciences Inc Prognose

Kursziel

By TipRanks

247.81% Vorteil

12-Monats-Prognose

Durchschnitt 10.33 USD 247.81%

Hoch 11 USD

Tief 10 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cellectar Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cellectar Biosciences Inc – Dist abgegeben haben.

Finanzen

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

1,063.79

↓-1.23%

JNJ

Johnson and Johnson

222.81

↓-0.32%

ABBV

AbbVie Inc

215.58

↑ +1.54%

UNH

UnitedHealth Group Inc

377.18

↓-0.59%

MRK

Merck & Co Inc.

115.96

↑ +0.86%

C Cellectar Biosciences Inc

Übersicht

Veränderung der Aktienkurses

Schlüsselkennzahlen

Empfehlungen

Cellectar Biosciences Inc Chart

Ähnliche Nachrichten

Peer-Vergleich

Cellectar Biosciences Inc Prognose

Kursziel

Rating-Konsens

Finanzen

Andere Aktien aus dem Sektor

C
Cellectar Biosciences Inc